GlassScriptPhysician profile
Cesar A Lassalle
NPI 1528257524
$15,550.68
in general payments reported to CMS, 2019-2025
56 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 81% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,734 · 2020: $1,467 · 2021: $2,804 · 2022: $2,111 · 2023: $2,056 · 2024: $1,080 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,916 · Travel and Lodging: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.56 |
| Travel and Lodging | $518.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,638.37 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Therapies |
| Nevro Corp. | $3,021.88 | 2019-2024 | Senza |
| Abbott Laboratories | $1,595.57 | 2019-2025 | Proclaim, Eterna, Axium |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,268.48 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $766.17 | 2019-2025 | Ztlido |
| Globus Medical, INC. | $704.13 | 2025 | Vyrsa V1, Senza |
| Medtronic, INC. | $554.02 | 2021-2024 | Intellis Adaptivestim |
| Abbvie INC. | $543.64 | 2021-2025 | |
| Vertos Medical, INC. | $482.97 | 2022-2024 | Mild Device Kit |
| Medtronic USA, INC. | $251.50 | 2019-2020 | |
| Grt US Holding, INC. | $236.12 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $207.94 | 2019-2021 | |
| Amgen INC. | $185.61 | 2019-2025 | Repatha |
| Protega Pharmaceutials INC | $185.32 | 2024-2025 | Roxybond |
| Allergan, INC. | $164.64 | 2019-2021 |
Show all 51 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Lassalle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.